Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. - Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; et al. (BMC cancer, 2019)